1. Scrip

AstraZeneca tired of life? Leaves London and reorganizes global R&D

 
• By Sukaina Virji

AstraZeneca's new CEO Pascal Soriot has wasted little time in putting his stamp on the troubled company since joining six months ago. Today saw the firm announcing sweeping changes to its R&D operations around the globe. This comes just three days before the unveiling of Mr Soriot's strategy review conclusions at an investor day in New York.

AstraZeneca's new CEO Pascal Soriot has wasted little time in putting his stamp on the troubled company since joining six months ago. Today saw the firm announcing sweeping changes to its R&D operations around the globe. This comes just three days before the unveiling of Mr Soriot's strategy review conclusions at an investor day in New York.

Under its new plans, AstraZeneca's small molecule and biologics R&D activities will be concentrated in three strategic centers: Cambridge, UK; Gaithersburg, Maryland and Mölndal, Sweden

More from Archive

More from Scrip

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Executives On The Move: Five CEOs, Three CFOs And Two CMOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Immunovant, Zymeworks and Cassava Sciences, among others, plus Zealand Pharma acquires chief scientific officer from Eli Lilly.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.